Hoth Therapeutics (NASDAQ:HOTH) Earns Buy Rating from D. Boral Capital
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 412.98% from the company’s current price. Separately, HC […]
Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 412.98% from the company’s current price. Separately, HC […]
